Biocompare (CompareNetworks) Acquires SEQanswers

Bruker Acquires DISQVER Metagenomic Sequencing Platform From Noscendo

July 17, 2026

Healthcare Services

Bruker acquired the DISQVER clinical metagenomics sequencing platform from Noscendo GmbH to expand its infection diagnostics portfolio. DISQVER enables whole-genome sequencing-based pathogen detection directly from blood samples and remains available for research use only while Bruker advances regulatory registration for diagnostic applications.

SeqOne Acquires Congenica

September 2, 2025

Software

SeqOne has acquired Congenica, a UK clinical genomics software company spun out of the Wellcome Sanger Institute, creating one of the largest pure‑play genomics software firms serving over 160 laboratories in 30+ countries. The combined business will integrate SeqOne's AI-driven NGS analysis platform with Congenica's clinical decision‑support tools to accelerate rare disease diagnoses and personalized cancer therapies while expanding SeqOne's UK presence.

CellBio Scientific Acquires BioChain

May 1, 2025

Biotechnology

CellBio Scientific, a provider of life science tools and research services, has acquired BioChain, a biospecimen collection, preparation, and analysis company based in Newark, California. The acquisition expands CellBio Scientific's capabilities in spatial genomics and biospecimen workflows, consolidating BioChain with System Biosciences and Acepix Biosciences to create a broader translational research platform.

ARCHIMED Acquires SeqCenter, Next-Generation Sequencing Provider

November 8, 2024

Biotechnology

Global healthcare private equity firm ARCHIMED has acquired SeqCenter, a Pittsburgh, Pennsylvania-based provider of next-generation DNA and RNA sequencing, through its MED Rise fund. ARCHIMED will leverage its MedValue playbook to accelerate SeqCenter's internationalization in Europe and Asia and support further development of advanced sequencing technologies; SeqCenter's founder rolled over a significant portion of his proceeds into the business.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Genesis Drug Discovery & Development Acquires Comparative Biosciences (CBI)

August 5, 2020

Biotechnology

Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group (GBG), has acquired Comparative Biosciences, Inc. (CBI), a Sunnyvale-based preclinical CRO. The acquisition adds GLP toxicology and safety pharmacology capabilities to GD3/GBG's integrated preclinical services, enabling end-to-end IND-enabling studies and expanding GD3's service offering.